Researchers at the University of Southampton and La Jolla Institute for Allergy & Immunology, California, have found that lung cancer patients with large amounts of a particular type of immune T-cell, called tissue-resident memory T-cells, in their tumour were 34 per cent less likely to die.

“Our results will also make the treatment pathway more reassuring for our patients. And if we can translate our finding into clinical practice, then we will also save patients unnecessary side effects and reduce costs to the NHS.” Christian Ottensmeier, Professor of Experimental Medicine, University of Southampton

 

Click here to read the full story